Alzheimer’s disease research has long focused on amyloid-β plaques and tau tangles. But in a peer-reviewed article published in PLOS Biology, Thomas S. Lewis, J. Wagner and J.J. Neher argue that changes in the brain’s blood vessels deserve closer attention. Their central point is that mapping molecular changes in vessels does not show, on its own, whether those changes impair the vessels’ function or contribute to disease.
The authors describe vascular dysfunction as a possible contributor to neuronal damage and degeneration, alongside the better-known disease hallmarks. They note that neurovascular problems are among the earliest abnormalities detected in people with Alzheimer’s and may appear before changes in biomarkers of amyloid and tau. Earlier studies they cite report reduced cerebral blood flow and impaired neurovascular coupling at prodromal stages. In advanced disease, regional blood flow may be reduced by as much as 45% in patients. These observations make vascular dysfunction a candidate part of disease progression, but do not establish what causes it.
Molecular profiling has helped researchers catalogue cellular and molecular changes in cerebral blood vessels. The article says much less is known about what drives those changes, how they relate to protein aggregation, how they develop over time, or how they translate into measurable functional deficits. The authors argue that molecular or cellular abnormalities alone cannot establish that a vessel is impaired. To close that gap, studies need to connect changes in vessel structure with measurements of mechanics, blood flow, tissue perfusion and oxygen delivery.
That connection also requires following changes over time. The authors point to in vivo models that allow vascular changes to be monitored and manipulated longitudinally, helping researchers investigate timing and causality. They caution that genetic mouse models do not reproduce the full complexity of human Alzheimer’s disease. They do, however, reproduce selected features, including amyloid-β deposition and cerebral amyloid angiopathy; some also show impaired neurovascular coupling and reduced cerebral blood flow. Findings in models could guide targeted studies in patients, the authors write.
One example of why direct measurement matters is remodeling of the vascular extracellular matrix, the material surrounding and supporting cells in vessel walls. The article describes changes in collagens, laminins, fibronectin, proteoglycans and basement membrane proteins in aging and Alzheimer’s. Some may be detectable in cerebrospinal fluid. Because this matrix also helps regulate vessel function, changes to its composition could affect arterial stiffness, endothelial signaling and other processes. Amyloid deposition in vessel walls may also affect elasticity, perivascular clearance and inflammation. These are plausible routes to altered blood flow, the authors say, but biological plausibility is not proof of physiological dysfunction. They warn that functional effects have often been inferred from molecular or tissue features rather than measured directly.
No single imaging method captures every level of vascular function. Two-photon microscopy can show individual vessels and cells in real time, but covers only small cortical areas. Functional MRI can map blood flow across the brain at lower spatial resolution and cannot measure passive vessel properties such as stiffness. High-frequency ultrasound can resolve individual cardiac cycles and estimate arterial stiffness and vascular resistance; contrast-enhanced ultrasound can also assess microvascular perfusion and help reconstruct the functional vascular network. The authors present these methods as complementary, with a full picture requiring measurements to be combined across scales. That integration is technically demanding and calls for different equipment and expertise, as well as matching data from the same animal.
The proposed framework is intended to help determine whether vascular changes are causes, amplifiers or consequences of Alzheimer’s pathology. If future work establishes those links, tracking vascular changes over time could help identify earlier biomarkers, clarify disease mechanisms and reveal stages when interventions to preserve or restore perfusion could be tested. The authors say the same approach may also matter for healthy aging and other neurodegenerative diseases. Their emphasis is on moving from a map of what changes in brain vessels to evidence about what those changes do.